Imeik Technology Development Co Ltd
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
26 / 1361
Position in country
880 / 7387
Return on Assets, %
27.6
-40.3
Net income margin, %
63.3
-180
EBITDA margin, %
74.1
-168.2
Debt to Equity, %
0.8
3.2
Intangible assets and goodwill, %
5.2
0.2
Revenue CAGR 3Y, %
59.3
12.5
Total Equity change 1Y, %
5.5
-9
Revenue Y, % chg
40.6
0
P/E
33.7
31
P/BV
9.8
1.8
P/S
21.8
10.3
EV/S
20.5
7.5
EV/EBITDA
28.3
-1.6
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
44.6
131.1
Forward P/E
23.5
21.4
Dividend Yield, %
1.1
1.1
Forward Dividend Yield, %
0.2
0.1
Expected dividend per share
0.5
0
Payout Ratio, %
26.8
0
Competitors
Ranks
-
Imeik Technology Development Co Ltd
00%
-
Chongqing Zhifei Biological Products Co Ltd
00%
-
Shanghai RAAS Blood Products Co Ltd
00%
-
Hualan Biological Engineering Inc
00%
-
Beijing Tiantan Biological Products Corp Ltd
00%
-
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
00%
-
Akeso Inc
00%
-
Gan & Lee Pharmaceuticals
00%
-
Innovent Biologics Inc
00%
-
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
China
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
8665.4
Ticker
300896.SZ
ISIN
CNE100004868
IPO date
2020-09-28
Availability on Russian exchanges
No
Reporting for
2024-03-19
Date fact. publication of reports
2023-12-31
Company Description
Imeik Technology Development Co Ltd is a China-based company mainly engaged in the research and development, production and sales of biomedical materials. The Company focuses on the development and transformation of biomedical materials, and is committed to the development of biomedicine such as recombinant proteins and peptides. The Company has realized the industrialization of injection-type sodium hyaluronate series products and polydioxanone facial implants, and has established a product technology transformation platform for biomedical materials such as medical chitosan and polylactic acid. The Company's self-developed products are mainly aimed at the repair of fold skin on the face and neck. The clinical applications of its products cover medical cosmetology, surgical repair, and treatment of metabolic diseases. The Company mainly conducts its businesses in the China market.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: